(1332-A) Large Scale Screening of Drug Candidates from Multiple Modalities using Biophysical Technologies in Early-Stage Drug Discovery
Monday, February 5, 2024
12:00 PM – 1:00 PM EST
Location: Exhibit Halls AB
Abstract: A diverse array of biophysical technologies has been pivotal in early-stage drug discovery with their ability to unravel molecular interactions crucial for the understanding of drug-target interactions, thereby guiding, and accelerating a rational drug development trajectory. High throughput biophysical assays with the combination of orthogonal technologies like surface plasmon resonance (SPR) and fluorescence spectroscopy (TdF, DSF) enable the simultaneous evaluation of a myriad of molecular interactions such as binding affinities, kinetics, thermodynamics, and potential mechanism of action, expediting the identification of potential drug candidates. This presentation will focus on our group’s collaborative effort to develop, optimize, and utilize large-scale biophysical assays based on SPR and TdF/DSF, combined with solubility assay (Nephelometry) to screen and identify drug candidates from different modalities (fragments/small molecules/peptides) with variable expected potencies. The assay parameters are optimized based on modality to maximize efficiency and throughput. We will highlight how our team leveraged different capabilities to accelerate hit validation through evaluation of biophysical parameters.